Mitochondrial quality control in lung diseases: current research and future directions

作者全名："Liu, Jiliu; Wang, Junyi; Xiong, Anying; Zhang, Lei; Zhang, Yi; Liu, Yao; Xiong, Ying; Li, Guoping; He, Xiang"

作者地址："[Liu, Jiliu; Wang, Junyi; Xiong, Anying; Zhang, Lei; Zhang, Yi; Liu, Yao; Li, Guoping; He, Xiang] Southwest Jiaotong Univ, Affiliated Hosp, Peoples Hosp Chengdu 3, Chengdu Inst Resp Hlth,Lab Allergy & Precis Med,S, Chengdu, Peoples R China; [Liu, Jiliu; Wang, Junyi; Xiong, Anying; Zhang, Lei; Zhang, Yi; Liu, Yao; Li, Guoping; He, Xiang] ChongQing Med Univ, Chengdu Peoples Hosp, Dept Pulm & Crit Care Med, Branch Natl Clin Res Ctr Resp Dis 3,Affiliated Hos, Chengdu, Peoples R China; [Xiong, Ying] Sichuan Friendship Hosp, Dept Pulm & Crit Care Med, Chengdu, Peoples R China"

通信作者："Li, GP; He, X (通讯作者)，Southwest Jiaotong Univ, Affiliated Hosp, Peoples Hosp Chengdu 3, Chengdu Inst Resp Hlth,Lab Allergy & Precis Med,S, Chengdu, Peoples R China.; Li, GP; He, X (通讯作者)，ChongQing Med Univ, Chengdu Peoples Hosp, Dept Pulm & Crit Care Med, Branch Natl Clin Res Ctr Resp Dis 3,Affiliated Hos, Chengdu, Peoples R China.; Xiong, Y (通讯作者)，Sichuan Friendship Hosp, Dept Pulm & Crit Care Med, Chengdu, Peoples R China."

来源：FRONTIERS IN PHYSIOLOGY

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:001039690100001

JCR分区：Q2

影响因子：3.2

年份：2023

卷号：14

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：mitochondrial quality control; chronic obstructive pulmonary disease; lung cancer; idiopathic pulmonary fibrosis; therapeutic approaches

摘要："Lung diseases are a major global health problem, affecting millions of people worldwide. Recent research has highlighted the critical role that mitochondrial quality control plays in respiratory-related diseases, including chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF). In this review, we summarize recent findings on the involvement of mitochondrial quality control in these diseases and discuss potential therapeutic strategies. Mitochondria are essential organelles for energy production and other cellular processes, and their dysfunction is associated with various diseases. The quality control of mitochondria involves a complex system of pathways, including mitophagy, mitochondrial biogenesis, fusion/fission dynamics, and regulation of gene expression. In COPD and lung cancer, mitochondrial quality control is often involved in disease development by influencing oxidative stress and apoptosis. In IPF, it appears to be involved in the disease process by participating in the cellular senescence process. Mitochondrial quality control is a promising target for therapeutic interventions in lung diseases. However, there are conflicting reports on different pathological processes, such as the role of mitochondrial autophagy in lung cancer, which pose difficulties in the study of targeted mitochondrial quality control drugs. Additionally, there seems to be a delicate balance between the mitochondrial quality control processes in the physiological state. Emerging evidence suggests that molecules such as PTEN-induced putative kinase 1 (PINK1), parkin RBR E3 ubiquitin protein ligase (PRKN), dynamin-related protein 1 (DRP1), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-a), as well as the signaling pathways they affect, play an important role in respiratory-related diseases. Targeting these molecules and pathways could contribute to the development of effective treatments for lung diseases. In conclusion, the involvement of mitochondrial quality control in lung diseases presents a promising new avenue for disease treatment. Further research is needed to better understand the complex mechanisms involved in the pathogenesis of respiratory diseases and to develop targeted therapies that could improve clinical outcomes."

基金机构："National Natural Science Foundation of China [81970026, 82000029]; China Postdoctoral Science Foundation [2023M730799]; Chengdu High-level Key Clinical Specialty Construction Project [ZX20201202020]; Chengdu Science and Technology Bureau [2021-YF09-00102-SN]; Sichuan provincial administration of traditional Chinese medicine [2020JC0118, 2020LC0212]"

基金资助正文："Funding This work was supported by the National Natural Science Foundation of China (81970026, 82000029), China Postdoctoral Science Foundation (2023M730799), Chengdu High-level Key Clinical Specialty Construction Project (ZX20201202020), Chengdu Science and Technology Bureau (2021-YF09-00102-SN), Sichuan provincial administration of traditional Chinese medicine (2020JC0118, 2020LC0212)."